Search results
Results from the WOW.Com Content Network
The corresponding Bcl11a mouse gene is a common site of retroviral integration in myeloid leukemia, and may function as a leukemia disease gene, in part, through its interaction with BCL6.
B-cell CLL/lymphoma refers to a family of genes associated with certain types of lymphoma and leukemia.. Although named for B-cell chronic lymphocytic leukemia, they can be associated with other malignancies.
This gene is known as the BCL11A, and when people have Beta thalassemia, their bodies do not make enough adult hemoglobin. Casgevy uses precise gene editing of stem cells, and reduces the activity of BCL11A.
BCL11A: ENSG00000119866: C2H2 ZF: Known motif – In vivo/Misc source : DDRRGGAASTGARAV BCL11B: ENSG00000127152: C2H2 ZF: Known motif – High-throughput in vitro : GTGAACGBNDNNVCTACAC BCL6: ENSG00000113916: C2H2 ZF: Known motif – High-throughput in vitro : YGCTTTCKAGGAAH BCL6B: ENSG00000161940: C2H2 ZF: Known motif – High-throughput in ...
Gene editing therapies aimed at increasing fetal hemoglobin production in beta thalassemia as well as sickle cell anemia by inhibiting the BCL11A gene have been developed. [ 44 ] [ 45 ] Exagamglogene autotemcel , sold under the brand name Casgevy, is a gene therapy for the treatment of transfusion-dependent beta thalassemia developed by Vertex ...
In addition HbF levels are influenced by polymorphisms in the BCL11A gene [3] and in the MYB gene enhancer. [4] In HPFH the percentage of HbF varies from 0.8-1.0% to about 30% of the total hemoglobin, but levels as high as 100% can be seen in homozygotes for delta beta thalassemia. [citation needed]
Whilst it was known that BCL11A was involved with cancer, Thein was the first to show that BCL11A was associated with red blood cell disorders. [5] The 6q QTL contains single-nucleotide polymorphisms distributed across three linkage disequilibrium blocks, in an intergenic region between MYB and HBS1L . [ 1 ]
Stuart Holland Orkin is an American physician, stem cell biologist and researcher in pediatric hematology-oncology.He is the David G. Nathan Distinguished Professor of Pediatrics at Harvard Medical School.